Study #2021-0910
CNIS793E12201 daNIS-3: An Open-Label, Multi-Center, Phase II Platform Study Evaluating the Efficacy and Safety of NIS793 and Other New Investigational Drug Combinations with Standard of Care (SOC) Anti-Cancer Therapy for the Second Line Treatment of Meta
MD Anderson Study Status
Not Accepting
Treatment Agent
NIS793, Bevacizumab, Modified FOLFOX6, FOLFIRI, Tislelizumab
Description
The purpose of this study is to evaluate the preliminary efficacy and safety of NIS793 and other novel investigational combinations with standard of care (SOC) anti-cancer therapy vs SOC anti-cancer therapy for the second line treatment of mCRC. This study aims to explore whether different mechanisms of action may reverse resistance and improve responsiveness to the currently considered SOC anti-cancer therapy in the second line metastatic colorectal cancer (mCRC) setting.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Metastatic Colorectal Cancer
Study phase:
Phase II
Physician name:
Van Morris
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-844-513-2253
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.